Factors Affecting Platelet Count in Platelet-Rich Plasma

Year 2022, Volume: 36 Issue: 2, 159 - 166, 30.08.2022

Çiğdem Karadağ Sarı

https://doi.org/10.18614/deutip.1174537

Abstract

Introduction: The amount of platelet count in platelet-rich plasma (PRP) is very important for the concentration of growth factors, which play a major role in the effectiveness of PRP.
Aim: The aim of this study was to investigate the effects of demographic and clinical parameters on the number of platelets in PRP.
Materials And Methods: The data of 50 patients who received PRP in our stem cell center were scanned retrospectively in electronic environment. Demographic and clinical parameters (age, gender, body mass index, blood group, comorbidities, hypertension, coronary heart disease and diabetes, alcohol and cigarette usage) of the patients were recorded.

Results: The results of the correlation analysis performed to evaluate whether there was a relationship between age and BMI with regards to platelet count in PRP revealed no statistical significance (p>0.05). Analysis of Mann Whitney-U and Kruskal Wallis-H showed that there was a statistically significant difference in terms of platelet count, gender, presence of hypertension and coronary artery disease (p<0.05). It was observed that the mean platelet count of female patients was higher than that of male patients, and the presence of hypertension and coronary artery disease also caused a decrease in platelet count with a statistically significance (p<0.05).

Conclusion: According to the results of this study one can conclude that gender, presence of hypertension and coronary artery disease were correlated with platelet count of PRP. Additionaly the demographic and clinical findings such as age, BMI, blood group, diabetes mellitus, smoking and alcohol consumption had no significant effect on platelet count in PRP.

Keywords

PRP, platelet rich plasma, cell count, Platelet Derived Growth Factor

References

• 5. Sánchez-González DJ, Méndez-Bolaina E, Trejo-Bahena NI. Platelet-rich plasma peptides: key for regeneration. Int J Pept. 2012;2012:1–10.
• 6. Rachul C, Rasko JEJ, Caulfield T. Implicit hype? Representations of platelet rich plasma in the news media. PLoS One. 2017;12:e0182496.
• 7. Chahla J, Cinque ME, Piuzzi NS, et al. A call for standardization in platelet-rich plasma preparation protocols and composition reporting: a systematic review of the clinical orthopaedic literature. J Bone Joint Surg Am. 2017;99:1769–79.
• 8. Magalon J, Bausset O, Serratrice N. Characterization and comparison of 5 platelet-rich plasma preparations in a single-donor model. Arthroscopy. 2014;30:629–38.
• 9. Zlotnicki JP, Geeslin AG, Murray IR, et al. Biologic treatments for sports injuries ii think tank-current concepts, future research, and barriers to advancement, part 3: articular cartilage. Orthop J Sports Med. 2016;4:232596711664243.
• 10. Milants C, Bruyère O, Kaux J-F. Responders to platelet-rich plasma in osteoarthritis: a technical analysis. Biomed Res Int. 2017;2017:1–11.
• 11. Salemi S, Rinaldi C, Manna F, Guarneri GF, Parodi PC. Reconstruction of lower leg skin ulcer with autologous adipose tissue and trombosit-rich plasma. J Plast Reconstr Aesthet Surg. 2008; 61(12):1565-7.
• 12. Cervelli V, Gentile P, De Angelis B, Calabrese C, Di Stefani A, Scioli MG, et al Application of enhanced stromal vascular fraction and fat grafting mixed with PRP in post-traumatic lower extremity ulcers. Stem Cell Res. 2011; 6(2):103-11.
• 13. Louis ML, Magalon J, Jouve E, et al. Growth factors levels determine efficacy of platelets rich plasma injection in knee osteoarthritis: a randomized double blind noninferiority trial compared with viscosupplementation. Arthroscopy. 2018;34:1530–40.
• 14. Saad Setta H, Elshahat A, Elsherbiny K, et al. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. Int Wound J. 2011;8:307–12.
• 15. Cervelli V, Gentile P, Scioli MG, Grimaldi M, Casciani CU, Spagnoli LG. Application of platelet rich plasma in plastic surgery: clinical and in vitro evaluation. Tissue Eng Part C Methods. 2009; 15(4):625e34. 16. Moojen DJ, Everts PA, Schure RM, et al. Antimicrobial activity of platelet-leukocyte gel against Staphylococcus aureus. J Orthop Res. 2008;26:404–10.
• 17. Magalon J, Velier M, Francois P, et al. Comment on “Responders to platelet-rich plasma in osteoarthritis: a technical analysis”. Biomed Res Int. 2017;2017:1–3.
• 18. Lee VS, Tarassenko L. An optical method for the determination of platelet count in platelet samples contaminated with red blood cells. J Biochem Biophys Methods. 1992;24:215–23.
• 19. Yutaka Kitamura, Masashi Suzuki, Tsuneyuki Tsukioka et al. Spectrophotometric determination of platelet counts in platelet-rich plasma, International Journal of Implant Dentistry. 2018; 4:29.
• 20. Emily A Sundman, Brian J Cole, Lisa A Fortier. Growth factor and catabolic cytokine concentrations are influenced by the cellular composition of platelet-rich plasma, Am J Sports Med. 2011 Oct;39(10):2135-40.
• 21. Gernot Weibrich, Wilfried K G Kleis, Walter E Hitzler, Gerd Hafne. Comparison of the platelet concentrate collection system with the plasma-rich-in-growth-factors kit to produce platelet-rich plasma: a technical report, Int J Oral Maxillofac Implants. 2005;20(1):118-23.